Our finding that HSP90/AXL/eIF4E-regulated UPR fosters tumor evolution and heterogeneity provides a conceptual framework for developing rational therapeutic strategies to treat KRAS-mutant lung cancer. The gene discussed is AXL; the disease is lung carcinoma.